*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
Through the Alnylam Assist® program through [January 2026].
Individual insurance coverage may vary.
Alnylam Assist® can help PH1 patients prescribed OXLUMO®:
Start treatment with OXLUMO.
Understand their benefits and coverage, as well as eligibility for financial assistance options such as the Commercial Copay Program.*†
Connect with Alnylam for ongoing information and product support.
Learn more about PH1 and treatment with OXLUMO.
An Alnylam Field Reimbursement Director can provide education about billing, coding, coverage, and reimbursement for OXLUMO.
PH1=primary hyperoxaluria type 1.
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist® Commercial Copay Program. Out-of-pocket costs for the administration of OXLUMO will not be covered for patients residing where it is prohibited by law or where otherwise restricted.
Financial Assistance Programs
Alnylam Assist® offers financial assistance programs for eligible patients. After being prescribed an Alnylam product (OXLUMO), your patient can talk to an Alnylam Case Manager to learn more. These financial assistance programs may include*:
- Commercial Copay Program: Covers certain out-of-pocket costs for eligible patients with commercial insurance†
- Patient Assistance Program (PAP): Provides Alnylam product (OXLUMO) at no cost to eligible patients, primarily the uninsured, who meet specified financial criteria
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist® Commercial Copay Program. Out-of-pocket costs for the administration of Alnylam products will not be covered for patients residing where it is prohibited by law or where otherwise restricted.
The McKesson Corporation is the specialty distributor for OXLUMO. [CVS Specialty Pharmacy] and PANTHERx Rare are the specialty pharmacies within the limited distribution network.
Help your patients get started with OXLUMO with Alnylam Assist®
Fill out the Start Form available below—this will help your patient access the support services that Alnylam Assist® offers—with benefit verification notification usually within 2 business days.
Print, complete with your patient, and fax the Start Form to 1-833-256-2747
What happens next?
An Alnylam Case Manager will reach out to you and your patient within 2 business days and provide a benefit verification summary and information about coverage and financial assistance options, if needed.
The Alnylam Assist® team can send your patient’s OXLUMO prescription to a specialty pharmacy and/or provide you information about specialty distributors.
Alnylam Assist® offers support services for your patients prescribed OXLUMO:
Reimbursement and coverage services:
- Prior authorization, coding, reimbursement education, and patient-specific benefit verification
Financial assistance:
- Low- or no-cost programs for eligible patients,*† including:
- Alnylam Assist® Copay Program:
Covers certain out-of-pocket costs for eligible patients with commercial insurance - Alnylam Assist® Patient Assistance Program:
Provides OXLUMO at no cost for eligible patients, primarily the uninsured
- Alnylam Assist® Copay Program:
Support through the treatment journey:
- One-on-one assistance is available throughout your patients' treatment journey from the following team members:
- Case Managers
- Field Reimbursement Team
- Patient Education Liaisons (PELs)‡
Tell Me More About Alnylam Assist®
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist® Commercial Copay Program. Out-of-pocket costs for the administration of OXLUMO will not be covered for patients residing where it is prohibited by law or where otherwise restricted.
PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice.
Downloadable patient brochure
A guide to help your patients better understand their condition and navigate treatment with OXLUMO.
Download the OXLUMO patient brochure for more information.
WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?
Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.
Patient advocacy organizations
Help your patient expand their network and stay informed by connecting them with independent patient advocacy organizations.
We hope you find the resources mentioned here helpful. Alnylam Pharmaceuticals is not affiliated with any of these organizations. By listing these resources, Alnylam Pharmaceuticals is not endorsing any particular service or group, and we are not responsible for the content of these sites or services. They are provided for informational purposes and should not replace a doctor’s medical advice.
